Stoke Therapeutics, Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveSep 30 →InsidersNo open-market buys. 8 insiders sold $8.4M, 43 of 70 sales on a 10b5-1 plan.→HoldersBlackRock 9.4%RTW Investments 9.0%FMR 8.5%→Financing →PeersClosest companies: RLAY, PRAX, ALEC→
From the filings
Figures
- Revenue
- $27.6Mlast 12 months
- Net income
- −$207.9Mlast 12 months
- Operating cash flow
- −$146.8Mlast 12 months
- Cash and equivalents
- $110.0Mat the last balance sheet
- Shares outstanding
- 62.4M shareson issue